ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2472

Are Anti-centromere Antibodies (aCENP) Predictive of Systemic Sclerosis Development in Patients Without Raynaud´s Phenomenon?

Andrea Alvear-Torres1, María José Martínez-Becerra2, María Carmen Vegas-Sánchez3, Sheila Recuero-Díaz1, María Pérez-ferro4 and Olga Sánchez-Pernaute5, 1Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, 2Department of Immunology. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, 3Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, 4Department of Rheumatology. Hospital Universitario Rey Juan Carlos, Madrid, Spain, 5Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain

Meeting: ACR Convergence 2024

Keywords: Autoantibody(ies), Raynaud's phenomenon, Scleroderma, Systemic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Anti-centromere (aCENP) antibodies are considered highly specific of systemic sclerosis (SSc), typically defining a limited cutaneous phenotype, usually associated to Raynaud´s phenomenon (RP). It is less understood the significance of these antibodies in the abscence of RP. Our aim in this study was to describe manifestations and outcomes in patients testing positive for aCENP over a five years period.

Methods: We carried out a review of charts of all patients with positive tests for aCENP antibodies detected at our Institution between 2015 and 2019. Data are shown in mean ± SEM, and frequencies. Two-sample t test and Chi2 were used for comparisons.

Results: The population comprised 298 cases, of whom 204 were available for follow-up. Eighty seven % were women. Mean age at study entry was 65,4 ± 0,9 y.o. First manifestation was RP in 84 patients (36% of the cohort). Time from aCENP detection to study entry was 1,6 ± 0,2 yrs., and 63 patients (21%) fulfilled SSc classification criteria at that moment.

At first evaluation, 192 patients (85%) did not have skin involvement, although 46 (24%) of them fulfilled SSc criteria. Only 19 patients (9%) had sclerodactily, out of whom 14 cases fulfilled SSc criteria. Ten patients had limited SSc with proximal to metacarpophalangeal joints involvement and 1 additional patient had diffuse SSc.

Interestingly, 97 patients (44%) did not report RP at study entry (as compared to 119 patients with this symptom).

The presence of RP was associated with a higher frequency of fulfillment of SSc criteria at study entry (59 patients, 50% of cases vs 4 patients, 4%, in the subgroup of cases without RP (p 0.001).

Out of 153 nailfold videocapillaroscopies (NVC) performed during workup only 15% (23 cases) were normal. An abnormal NVC pattern was found in 96 of the patients with RP (91%) as compared with 33 of the patients without RP (62%), (p < 0.001). No significant differences were found between RP and non-RP patients as regards to non-SSc specific abnormalities and early SSc patterns, while the presence of an active or a late pattern were strongly associated to the RP group (p 0.001, p 0.016 respectively).

After 3.6 ± 0.2 yrs of follow-up (732.2 patient-year) 90 patients fulfilled SSc classification criteria (corresponding to 22 new cases).

RP was associated to the development of SSc during follow-up (68% of the patients vs. 12% of those without RP, p < 0.001). A normal pattern in the NVC was associated to a lack of fulfillment of SSc criteria at the end of follow-up (NPV of 89,5% , p < 0.001).

Conclusion: Our results suggest that all patients with aCENP antibodies should undergo an NVC, even in the absence of RP, since many of them have an underlying vasculopathy.


Disclosures: A. Alvear-Torres: None; M. Martínez-Becerra: None; M. Vegas-Sánchez: None; S. Recuero-Díaz: None; M. Pérez-ferro: None; O. Sánchez-Pernaute: None.

To cite this abstract in AMA style:

Alvear-Torres A, Martínez-Becerra M, Vegas-Sánchez M, Recuero-Díaz S, Pérez-ferro M, Sánchez-Pernaute O. Are Anti-centromere Antibodies (aCENP) Predictive of Systemic Sclerosis Development in Patients Without Raynaud´s Phenomenon? [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/are-anti-centromere-antibodies-acenp-predictive-of-systemic-sclerosis-development-in-patients-without-raynauds-phenomenon/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-anti-centromere-antibodies-acenp-predictive-of-systemic-sclerosis-development-in-patients-without-raynauds-phenomenon/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology